Brazilian red propolis exerts a cytotoxic action against prostate cancer cells and upregulates human monocyte functions

Association between circulating immune cells and the risk of prostate cancer: a Mendelian randomization study

Background

There is still limited research on the association between immune cells and the risk of prostate cancer. Further investigations are warranted to comprehend the intricate associations at play.

Methods

We used a bidirectional two-sample Mendelian randomization (MR) analysis to investigate the causal relationship between immune cell phenotypes and prostate cancer. The summary data for immune cell phenotypes was derived from a study cohort, including 3,757 individuals from Sardinia with data on 731 immune cell phenotypes. The summary data for prostate cancer were obtained from the UK Biobank database. Sensitivity analyses were conducted, and the combination of MR-Egger and MR-Presso was used to assess horizontal pleiotropy. Cochran's Q test was employed to evaluate heterogeneity, and the results were subjected to FDR correction.

Results

Our study identified two immune cell phenotypes significantly associated with the risk of prostate cancer, namely CD25 on naive-mature B cells (OR = 0.998, 95% CI, 0.997-0.999, P = 2.33E-05, FDR = 0.017) and HLA DR on CD14- CD16- cells (OR = 1.001, 95% CI, 1.000-1.002, P = 8.01E-05, FDR = 0.03). When adjusting FDR to 0.2, we additionally found six immune cell phenotypes influencing the incidence of prostate cancer. These include FSC-A on B cells (OR = 1.002, 95% CI, 1.001-1.002, P = 7.77E-04, FDR = 0.133), HLA DR on plasmacytoid dendritic cells (OR = 1.001, 95% CI, 1.000-1.001, P = 0.001, FDR = 0.133), CD14+ CD16- monocyte % monocytes (OR = 1.002, 95% CI, 1.001-1.003, P = 0.001, FDR = 0.133), and HVEM on effector memory CD4+ T cells (OR = 1.001, 95% CI, 1.000-1.002, P = 0.002, FDR = 0.169), which are positively correlated with the risk of prostate cancer. Conversely, CD25 on IgD+ B cells (OR = 0.998, 95% CI, 0.997-0.999, P = 0.002, FDR = 0.169) and Monocytic Myeloid-Derived Suppressor Cells AC (OR = 0.999, 95% CI, 0.999-1.000, P = 0.002, FDR = 0.17) are negatively correlated with the risk of prostate cancer.

Conclusion

This study has revealed causal relationships between immune cell phenotypes and prostate cancer, supplying novel insights that might aid in identifying potential therapeutic targets of prostate cancer.

Effects of caatinga propolis from Mimosa tenuiflora and its constituents (santin, sakuranetin and kaempferide) on human immune cells

ETHNOPHARMACOLOGICAL RELEVANCE

Propolis is a bee product used in folk medicine to treat inflammatory diseases. Diverse types of propolis are produced worldwide depending on the local flora. Recently, research has been focused on a propolis sample produced in the northeast Brazilian "caatinga" from Mimosa tenuiflora, popularly known as "jurema-preta".

AIM OF THE STUDY

A possible immunomodulatory/anti-inflammatory action was analyzed to verify the potential of M. tenuiflora propolis (MP) and its constituents (santin, sakuranetin and kaempferide) in human immune cells under baseline conditions or in LPS-stimulated cells.

METHODS

Cell viability, cytokine (TNF-α, IL-1β, IL-6, IL-8, IL-10) production and intracellular pathways (NF-kB and p38 MAPK) were evaluated.

RESULTS

Under basal conditions, MP and sakuranetin did not affect cytokine production; santin enhanced TNF-α, IL-1β, IL-6, while kaempferide inhibited IL-8 and IL-10. In LPS-stimulated cells, MP and its compounds exerted an inhibitory activity on TNF-α and IL-1β, while no effects were seen on IL-6 and IL-8. Santin and kaempferide inhibited IL-10 production. No significant differences were seen on NF-kB and p38 MAPK intracellular pathways.

CONCLUSION

Data indicated the immunomodulatory action of caatinga propolis and its constituents at noncytotoxic concentrations, specifically an anti-inflammatory activity in LPS-treated cells by inhibiting cytokine production. Santin, sakuranetin and kaempferide appeared to be involved in MP activities.